Nutriband Inc. has signed an agreement to sell a 90% interest in its subsidiary, Pocono Pharmaceutical, to EarthVision Bio for $5 million USD. As part of the deal, Nutriband Inc. shareholders will retain a 10% shareholding in EarthVision Bio following the acquisition. The transaction is expected to close by December 31, 2025. Proceeds from the sale will be used by Nutriband Inc. to support the continued development of AVERSA Fentanyl, an abuse-deterrent opioid patch. EarthVision Bio is focused on developing and commercializing sustainable product alternatives to plastic, molded fiber, wood, and paper, based on innovations by Dr. Gordon Moore and Dr. Hans Franke.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nutriband Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9617606-en) on December 29, 2025, and is solely responsible for the information contained therein.
Comments